Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Gains from Investment Securities: 2016-2025

Historic Gains from Investment Securities for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to -$30,000.

  • Ultragenyx Pharmaceutical's Gains from Investment Securities fell 101.79% to -$30,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 67.88%. This contributed to the annual value of $3.5 million for FY2024, which is 30.88% down from last year.
  • Ultragenyx Pharmaceutical's Gains from Investment Securities amounted to -$30,000 in Q3 2025, which was up 84.13% from -$189,000 recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Gains from Investment Securities' 5-year high stood at $4.0 million during Q1 2023, with a 5-year trough of -$1.2 million in Q3 2022.
  • For the 3-year period, Ultragenyx Pharmaceutical's Gains from Investment Securities averaged around $1.0 million, with its median value being $398,000 (2023).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first spiked by 586.46% in 2022, then slumped by 539.11% in 2024.
  • Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Gains from Investment Securities stood at $455,000 in 2021, then plummeted by 50.55% to $225,000 in 2022, then increased by 20.44% to $271,000 in 2023, then plummeted by 539.11% to -$1.2 million in 2024, then slumped by 101.79% to -$30,000 in 2025.
  • Its last three reported values are -$30,000 in Q3 2025, -$189,000 for Q2 2025, and $3.0 million during Q1 2025.